All-trans-retinoic acid: A phase II radiation therapy oncology group study (RTOG 91-13) in patients with recurrent malignant astrocytoma

Journal of Neuro-Oncology

Volumn 34, Issue 2, 1997, Pages 193-200

  Phuphanich, Surasak ^a,b   Scott, Charles ^a,c   Fischbach, A Jennifer ^a,d   Langer, Corey ^a,e   Yung, W K Alfred ^a,f  

^a Radiation Therapy Oncology Group   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c RTOG Statistics Department

^d LDS HOSPITAL   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

All retinoic acid; Malignant gliomas

Indexed keywords

ANTINEOPLASTIC AGENT; RETINOIC ACID;

ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTROCYTOMA; BLEEDING; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHEILITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVITIS; DISEASE COURSE; DRY SKIN; FATIGUE; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; NAUSEA; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SURVIVAL TIME; TUMOR REGRESSION; VOMITING;

ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROLOGIC EXAMINATION; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE; TRETINOIN;

EID: 0030994384     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005765915288     Document Type: Article

References (37)

1. Walker MD, Alexander G Jr, Hunt WE, Leventhal CM, Mahaley MS Jr, Mealey J, Norrell HA: Evaluation of mithramycin in the treatment of anaplastic gliomas. J Neurosurg 44: 655-667, 1976
2. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahalley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49; 333-343, 1978
3. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiotherapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597, 1993
4. Lippman SM, Kessler JF, Meyskens FL Jr: Retinoids as preventive and therapeutic anticancer agents (Part II). Cancer Treat Rep 17: 493-515, 1987
5. Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL Jr: Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 123: 201-204, 1987
6. Lippman SM, Meyskens FL: Results of the use of vitamin A and retinoids in cutaneous malignancies. Pharmac Ther 40: 107-122, 1989
7. Lippman SM, Meyskens FL: Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 107: 499-501, 1987
8. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughan C, Toth BB, Kramer A, Dimery IW, Skipper P, Strong S: 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315: 1501-1505, 1986
9. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL: Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 318: 1633-1637, 1988
10. Lippman SM, Kessler JF, Al-Sarraf M, Alberts DS, Itri LM, Mattox D, Van Hoff DO: Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: A phase II randomized trial. Invest New Drugs 6: 51-56, 1988
11. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY: U se of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572, 1988
12. Chomienne C, Ballerini P, Balitrand N, Amar M, Bernard JF, Boivin P, Daniel MT, Berger R, Castaigne S, Degos L: Retinoic acid therapy for promyelocytic leukemia. Lancet 746-747, 1989
13. Castaigne S, Chomienne C, Ballerini P, Huang ME, Daniel MT, Berger R, Miclea JM, Degos L: All-trans-retinoic acid: A novel differentiation therapy for acute promyelocytic leukemia (Abstract) Blood 117a, 1989
14. Yung WK, Lotan R, Lee P, Lotan D, Steck P: Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells. Cancer Research 49: 1014-1019, 1989
15. Olson JA; Adverse effects of large doses of vitamin A and retinoids. Semin Oncol 10: 290-293, 1983
16. Levin VA, Wilson DB, Crafts D, Norman D, Hoffer P, Spire JP: Criteria for evaluating malignant brain tumor patients undergoing chemotherapy. J Neurosurg 47: 329-335, 1977
17. Norman D, Enzmann D, Levin VA, Wilson CB, Newton TH: Computerized tomographic scanning in the evaluation of malignant gliomas under therapy. Radiol 121: 85-88, 1976
18. Caplan RJ, Pajak TF, Cox JD: Analysis of the probability and risk of cause-specific failure. Int J Radiat Oncol Biol Phys 29: 1183-1186, 1994
19. Smith MA, Adamson PC, Balis FM, Feusner J, Aronson L, Murphy RF, Horowitz ME, Reaman G, Mannond GD, Fenton RM, Cannaghan GD, Hittleman WN, Poplack DG: Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 10: 1666-1673, 1992
20. Lee JS, Newman RA, Lippman SM, Huber MH, Minor J, Raber MN, Krakoff IH, Hong WK: Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol 11: 959-966, 1993
21. Kahn MJ, Luginbuhl W, Gaines L, Bratschi J, Bavaria J, Kaiser L, Treat J: Leukocytosis associated with all-trans-retinoic acid therapy in metastatic non-small cell lung cancer. J Natl Cancer Inst 84: 1669-1671, 1992
22. Frankel SR, Eardley A, Lauwers G: The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 117: 292-296, 1992
23. Koike T, Tatewaki WH, Aoki A, Yoshimoto H, Yagaisawa K, Hashimoto S, Furukawa T, Sastoh H, Takahashi M, Li-bo Y, Ying W, Shibata A: Brief report: Severe symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 327: 385-387, 1992
24. Koch HF: Biochemical treatment of precancerous oral lesions: The effectiveness of various analogues of retinoic acid. J Maxillofac Surg 6: 59-63, 1978
25. Band PR, Besner JG, Leclaire R, Girad C, Biorio G, Deshamps M, Gelinas M, Larochelle D: Phase I study on 13-cis-retinoic acid toxicity. Cancer Treat Rep 66: 1759-1761, 1982
26. Yung WK, Simaga M, Levin VA: 13-cis-retinoic acid: A new and potentially effective agent for recurrent malignant astrocytomas. (Abstract) Proc Am Assoc Cancer Res 12: A497, 1993
27. Atiba J, Jamil S, Meyskens FL Jr, Cho J, Armentrout S, Berkson P, Wong S-F, Neal J: Transretinoic acid (tRA) in the treatment of malignant gliomas (MG): A phase II study (Abstract) Proc Am Soc Clin Oncol 13: A501, 1994
28. Westarp ME, Westarp MP, Bollag W: Effect of six retinoids and retinoic acid catabolic inhibitor liarozole on two glioblastoma cell lines, and first experience in malignant brain tumor patients. (Abstract) Fourth International Congress on Anti-cancer Chemotherapy, February 2-5, 1993, Paris, France, 116
29. Hoffman W, Rodemann HP, Schiller U: Retinoid and Interferon - an Induced Modulation of Proliferation and Differentiation in Human Tumor Cell Lines. (Abstract) Second International Cancer Chemo Prevention Conference, April 28-30, 1993, Berlin, Germany, 99
30. Kalin JR, Wells MJ, Hill DL: Effects of phenobarbital, 3-methylcholanthrene, and retinoid pretreatment on disposition of orally administered retinoids in mice. Drug Metab Dispos 12: 63-67, 1984
31. Siegenthaler G, Saurate JH: Plasma and skin carriers for natural and synthetic retinoids. Arch Dermatol 123: 1690a-1692a, 1987
32. Hirschel Scholz S, Siegenthaler G, Saurat JH: Ligand-specific and non-specific in vivo modulation of human epidermal cellular retinoid acid binding protein (CRABP). Eur J Clin Invest 19: 220-227, 1989
33. Hirschel Scholz S, Siegenthaler G, Saurat JH: Isotretinoin differs from other synthetic retinoids in its modulation of human cellular retinoid acid binding protein (CRABP). Br J Dermatol 120: 639-644, 1989
34. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Hatthay KK, Ramsay NKC, Reynolds CP: Phase I trial of 13 cis-retinoic acid in children with neuroblastoma following bone marrow transplanlation. J Clin Oncol 13: 894-900, 1995
35. Reynolds CP, Schlinder P, Jones D, Gentile J, Proffitt R, Einhorn P: Comparison of 13-cis-retinoic acid to trans-retinoic acid using human neuroblastoma cell lines. In: Evans A, Biedler JL, Brodeur G et al. (eds) Advances in Neuroblastoma Research 4. New York, NY, Wiley, 1994; 237-244
36. Muindi J, Frankel SR, Miller W Jr, Jukubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP Jr: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid 'resistance' in patients with acute promyelocytic leukemia. Blood 79: 299-303, 1992
37. Smith MA, Parkinson DR, Cheson BD, Friedman MA: Retinoids in cancer therapy. J Clin Oncol 10: 839-864, 1992